A protease-resistant Escherichia coli asparaginase with outstanding stability and enhanced anti-leukaemic activity in vitro

L-Asparaginases (ASNases) have been used as first line drugs for paediatric Acute Lymphoblastic Leukaemia (ALL) treatment for more than 40 years. Both the Escherichia coli (EcAII) and Erwinia chrysanthemi (ErAII) type II ASNases currently used in the clinics are characterized by high in vivo instabi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Maggi, Maristella, Mittelman, Steven D., Parmentier, Jean Hugues, Colombo, Giorgio, Meli, Massimiliano, Whitmire, Jeannette Marie, Merrell, D. Scott, Whitelegge, Julian, Scotti, Claudia
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5670125/
https://ncbi.nlm.nih.gov/pubmed/29101342
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-15075-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados